Antibodies News and Research

RSS

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

A new study by researchers from the Scripps Research Institute and Novavax Inc. in the US affirms the structural integrity of the full-length SARS-CoV-2 spike glycoprotein immunogen. It enables the interpretation of immune responses to this multivalent nanoparticle immunogen. Their results are currently available on bioRxiv preprint server.

9 Aug 2020

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

NVX-CoV2373, a recombinant nanoparticle vaccine developed by Novavax and manufactured at Emergent Biosolutions, was found to be well tolerated and immunogenic – inducing T-cell response and neutralization antibodies four-fold higher than the mean observed in hospitalized coronavirus disease (COVID-19) patients, shows a recent study available on the medRxiv* preprint server.

9 Aug 2020

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

Researchers at Ligandal Inc., the University of California San Francisco and Toyota Technological Institute at Chicago, have designed novel synthetic peptides that potently inhibit the ability of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to infect host cells.

9 Aug 2020

New platform shows potential to generate most effective vaccines with fewest side effects

The ongoing COVID-19 pandemic is shining a bright spotlight on vaccine development. As numerous vaccines race through clinical trials, physicians and researchers continue to work on developing new vaccine technologies to generate the most effective vaccines with the fewest side effects.

7 Aug 2020

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

A nanomedicine-based strategy for chemo-immunotherapy (CIT) of glioblastoma (GBM), which has the worst prognosis among brain tumors, was successfully developed.

7 Aug 2020

Study identifies five immune response markers that may predict COVID-19 patient outcomes

Galit Alter, PhD, Group Leader at the Ragon Institute of MGH, MIT and Harvard and Professor of Medicine at Harvard Medical School, and Helen Chu, MD, Associate Professor of Medicine, Division of Allergy and Infectious Diseases, University of Washington School of Medicine, and UW Medicine physician, have recently published a paper which identifies five immune response markers which, collectively, were able to correctly classify both convalescent COVID-19 patients and those who did not survive the disease.

7 Aug 2020

New type of immunotherapy shows promise for advanced skin cancer

A new type of immunotherapy for the skin cancer malignant melanoma shows promising results. Three severely ill patients are now long-term survivors.

7 Aug 2020

Test sites quickly attract thousands for COVID-19 vaccine study

Dr. Eric Coe jumped at the chance to help test a COVID-19 vaccine.

7 Aug 2020

Nanoparticle method captures and measures common marker of heart disease

Researchers at the University of Wisconsin-Madison have developed a method combining sticky nanoparticles with high-precision protein measurement to capture and analyze a common marker of heart disease to reveal details that were previously inaccessible.

7 Aug 2020

Immune system derails during severe course of COVID-19

Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction - rather, the immune response is caught in a continuous loop of activation and inhibition.

6 Aug 2020

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

6 Aug 2020

America’s obesity epidemic threatens effectiveness of any COVID vaccine

For a world crippled by the coronavirus, salvation hinges on a vaccine.

6 Aug 2020

Carefully engineered spike protein can help develop COVID-19 vaccine

The experimental vaccine against SARS-CoV-2 that was the first to enter human trials in the United States has been shown to elicit neutralizing antibodies and a helpful T-cell response with the aid of a carefully engineered spike protein that mimics the infection-spreading part of the virus.

6 Aug 2020

Cats susceptible to and potential reservoirs for novel coronavirus

The study published on the preprint server bioRxiv in August 2020 shows that this is indeed taking place, with pet cats being infected and passing on the infection to contacts. It also offers the chance to see how the disease progresses in a susceptible host.

6 Aug 2020

Antibodies News and Research

Speed of Novavax vaccine development does not compromise quality of the SARS-CoV-2 immunogen

Encouraging results from Phase I NovaVax SARS-CoV-2 nanoparticle vaccine trial

Cutting edge synthetic peptides block SARS-CoV-2 (COVID-19)

New platform shows potential to generate most effective vaccines with fewest side effects

Nanomedicine-based strategy enhances anti-PD1 therapy to eradicate PTEN-negative GBM

Study identifies five immune response markers that may predict COVID-19 patient outcomes

New type of immunotherapy shows promise for advanced skin cancer

Test sites quickly attract thousands for COVID-19 vaccine study

Nanoparticle method captures and measures common marker of heart disease

Immune system derails during severe course of COVID-19

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

America’s obesity epidemic threatens effectiveness of any COVID vaccine

Carefully engineered spike protein can help develop COVID-19 vaccine

Cats susceptible to and potential reservoirs for novel coronavirus

A SARS-CoV-2 assay using plant proteins

NIH-Moderna investigational vaccine protects mice from infection with SARS-CoV-2

Evidence for antibody longevity in COVID-19 patients

New serological test for COVID-19 helps determine herd immunity, vaccine efficacy

Beneficial microbes reprogram the B cell repertoire that produce antibodies

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Immunology eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News